What is the optimal duration of ADT for unfavorable intermediate risk or high risk localized prostate cancer treated with SBRT instead of conventionally fractionated or hypofractionated RT?
Do you also give neoadjuvant, concurrent, and adjuvant ADT in the same manner as for non-SBRT EBRT?
Answer from: Radiation Oncologist at Academic Institution
Intermediate RiskThe available phase III data validating SBRT does not include concurrent ADT, however, I typically recommend the same duration of ADT as for fractionated EBRT based on generalization from this literature. I am not aware of any comparative trials proving the additional efficacy of AD...
Answer from: Radiation Oncologist at Academic Institution
This is a timely question. Currently, there are no published data to suggest that the duration of ADT can be altered in the context of ultrahypofractionation for either UIR or HR disease. Fundamentally, two facts and/or realities of evidence must be appreciated. First, it must be recognized that thu...
Comments
Radiation Oncologist at Lafayette Radiation Center
UFIR should get ADT regardless of modality. There ...
UFIR should get ADT regardless of modality. There ...
Radiation Oncologist at UW Carbone Cancer Center
ASCO this year is presenting a very interesting Ph...
ASCO this year is presenting a very interesting Ph...
Answer from: Radiation Oncologist at Academic Institution
Good discussion.
Perhaps the more pressing question we should be asking our urology colleagues is why they don't routinely offer medical intervention or refer to someone who will offer one when their surgical patients have UIR or more commonly, high or very high risk disease.
There seems to be a d...
Answer from: Medical Oncologist at Community Practice
Will give ADT based upon current NCCN guidelines.
Agree, no data suggests that there is a need to de...